BAX
Price
$24.39
Change
-$0.12 (-0.49%)
Updated
Oct 21, 11:03 AM (EDT)
Capitalization
12.67B
8 days until earnings call
Intraday BUY SELL Signals
LH
Price
$322.88
Change
-$0.25 (-0.08%)
Updated
Oct 21, 11:14 AM (EDT)
Capitalization
26.21B
7 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BAX vs LH

BAX vs LH Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BAX vs. LH commentary
Oct 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BAX is a Buy and LH is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BAX with price predictions
Oct 20, 2026

Aroon Indicator for BAX shows an upward move is likely

BAX's Aroon Indicator triggered a bullish signal on October 20, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 210 similar instances where the Aroon Indicator showed a similar pattern. In 143 of the 210 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 68%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 30, 2026. You may want to consider a long position or call options on BAX as a result. In 55 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.

The Moving Average Convergence Divergence (MACD) for BAX just turned positive on September 30, 2026. Looking at past instances where BAX's MACD turned positive, the stock continued to rise in 23 of 45 cases over the following month. The odds of a continued upward trend are 51%.

Following a +2.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where BAX advanced for three days, in 165 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.

Bearish Trend Analysis

The 10-day RSI Indicator for BAX moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 21 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 64%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 55 cases where BAX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 75%.

BAX moved below its 50-day moving average on October 20, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BAX crossed bearishly below the 50-day moving average on September 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.

BAX broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. BAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.042) is normal, around the industry mean (4.940). P/E Ratio (-11.841) is within average values for comparable stocks, (36.759). BAX's Projected Growth (PEG Ratio) (36.677) is very high in comparison to the industry average of (4.456). Dividend Yield (0.002) settles around the average of (0.005) among similar stocks. P/S Ratio (1.057) is also within normal values, averaging (56.074).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
a Summary for LH with price predictions
Oct 20, 2026

LH in upward trend: price rose above 50-day moving average on October 20, 2026

LH moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 25 of 40 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 62%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 06, 2026. You may want to consider a long position or call options on LH as a result. In 60 of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.

The Moving Average Convergence Divergence (MACD) for LH just turned positive on October 08, 2026. Looking at past instances where LH's MACD turned positive, the stock continued to rise in 24 of 52 cases over the following month. The odds of a continued upward trend are 46%.

Following a +1.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where LH advanced for three days, in 192 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 58 cases where LH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 60%.

The 10-day moving average for LH crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.

LH broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for LH entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.045) is normal, around the industry mean (64.051). P/E Ratio (26.551) is within average values for comparable stocks, (1.569). Projected Growth (PEG Ratio) (1.206) is also within normal values, averaging (3.473). LH has a moderately high Dividend Yield (0.009) as compared to the industry average of (0.002). P/S Ratio (1.876) is also within normal values, averaging (9.775).

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. LH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 47 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock slightly better than average.

The Tickeron PE Growth Rating for this company is 62 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

FUNDAMENTALS RATINGS
BAX vs LH: Fundamental Ratings
BAX
LH
OUTLOOK RATING
1..100
1326
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
11
Undervalued
PROFIT vs RISK RATING
1..100
10047
SMR RATING
1..100
9465
PRICE GROWTH RATING
1..100
1842
P/E GROWTH RATING
1..100
5562
SEASONALITY SCORE
1..100
8585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LH's Valuation (11) in the Servicestothe Health Industry industry is significantly better than the same rating for BAX (95) in the Medical Specialties industry. This means that LH’s stock grew significantly faster than BAX’s over the last 12 months.

LH's Profit vs Risk Rating (47) in the Servicestothe Health Industry industry is somewhat better than the same rating for BAX (100) in the Medical Specialties industry. This means that LH’s stock grew somewhat faster than BAX’s over the last 12 months.

LH's SMR Rating (65) in the Servicestothe Health Industry industry is in the same range as BAX (94) in the Medical Specialties industry. This means that LH’s stock grew similarly to BAX’s over the last 12 months.

BAX's Price Growth Rating (18) in the Medical Specialties industry is in the same range as LH (42) in the Servicestothe Health Industry industry. This means that BAX’s stock grew similarly to LH’s over the last 12 months.

BAX's P/E Growth Rating (55) in the Medical Specialties industry is in the same range as LH (62) in the Servicestothe Health Industry industry. This means that BAX’s stock grew similarly to LH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BAXLH
RSI
ODDS (%)
Bearish Trend 1 day ago
64%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
60%
Momentum
ODDS (%)
Bullish Trend 1 day ago
65%
Bullish Trend 1 day ago
60%
MACD
ODDS (%)
Bullish Trend 1 day ago
51%
Bullish Trend 1 day ago
46%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
69%
Bullish Trend 1 day ago
58%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
64%
Bullish Trend 1 day ago
54%
Advances
ODDS (%)
Bullish Trend 9 days ago
57%
Bullish Trend 1 day ago
57%
Declines
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 21 days ago
53%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
65%
Bearish Trend 1 day ago
49%
Aroon
ODDS (%)
Bullish Trend 1 day ago
68%
Bearish Trend 1 day ago
51%
COMPARISON
Comparison
Oct 21, 2026
Stock price -- (BAX: $24.51 vs. LH: $323.13)
Brand notoriety: BAX and LH are both not notable
BAX represents the Pharmaceuticals: Other, while LH is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: BAX: 202% vs. LH: 82%
Market capitalization -- BAX: $12.67B vs. LH: $26.21B
BAX [@Pharmaceuticals: Other] is valued at $12.67B. LH’s [@Medical Specialties] market capitalization is $26.21B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $154.74B. The market cap for tickers in the [@Medical Specialties] industry ranges from $27 to $4.39T. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.15B. The average market capitalization across the [@Medical Specialties] industry is $20.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BAX’s FA Score shows that 1 FA rating(s) are green while LH’s FA Score has 1 green FA rating(s).

  • BAX’s FA Score: 1 green, 4 red.
  • LH’s FA Score: 1 green, 4 red.
According to our system of comparison, LH is a better buy in the long-term than BAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BAX’s TA Score shows that 4 TA indicator(s) are bullish while LH’s TA Score has 4 bullish TA indicator(s).

  • BAX’s TA Score: 4 bullish, 6 bearish.
  • LH’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, LH is a better buy in the short-term than BAX.

Price Growth

BAX (@Pharmaceuticals: Other) experienced а -1.53% price change this week, while LH (@Medical Specialties) price change was +3.03% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.41%. For the same industry, the average monthly price growth was -3.31%, and the average quarterly price growth was +7.68%.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.69%. For the same industry, the average monthly price growth was -4.76%, and the average quarterly price growth was +43.77%.

Reported Earning Dates

BAX is expected to report earnings on Oct 29, 2026.

LH is expected to report earnings on Oct 28, 2026.

Industries' Descriptions

@Pharmaceuticals: Other (+1.41% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Medical Specialties (+0.69% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

View a ticker or compare two or three
BAX
Daily Signal:
Gain/Loss:
LH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MDIA1.040.02
+1.96%
Mediaco Holding
NEOG11.720.09
+0.77%
Neogen Corp
GME26.470.03
+0.11%
GameStop Corp
SNES0.69-0.01
-1.53%
SenesTech Inc.
HNRG11.34-0.32
-2.74%
Hallador Energy Company

BAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BAX has been loosely correlated with LUNG. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if BAX jumps, then LUNG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BAX
1D Price
Change %
BAX100%
-1.92%
LUNG - BAX
53%
Loosely correlated
+4.00%
ICUI - BAX
52%
Loosely correlated
-0.10%
STE - BAX
51%
Loosely correlated
+1.45%
SYK - BAX
51%
Loosely correlated
+2.17%
BDX - BAX
49%
Loosely correlated
+1.60%
More

LH and

Correlation & Price change

A.I.dvisor indicates that over the last year, LH has been closely correlated with DGX. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if LH jumps, then DGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LH
1D Price
Change %
LH100%
+1.35%
DGX - LH
74%
Closely correlated
+0.94%
SYK - LH
51%
Loosely correlated
+2.17%
STE - LH
50%
Loosely correlated
+1.45%
BAX - LH
46%
Loosely correlated
-1.92%
ATR - LH
43%
Loosely correlated
+0.91%
More